By bundling professional marketing services into device purchases, device manufacturers are hoping to take the edge off surgeonsโ concerns that the technology might gather dust, or could take years to pay off.
BTL launched its partnership with eRelevance in late 2015 to help cosmetic and other practices adding BTLโs Vanquish ME, Exilis Ultra 360, Ultra Femme 360 or Cellutone technologies market the devices. According to eRelevance, 130 practices have participated in the partnership.
The way it works is cosmetic surgeons who buy BTL devices get six months of marketing with eRelevance for free, then have to pay in the neighborhood of $10,000 to $20,000 annually to continue using eRelevanceโs customer marketing automation service. The proprietary service, which automates and leverages a practiceโs current customers, has helped BTL practices generate just over $16,000 in additional revenue, with an average of 19 more patient consultation requests per month.
Mr. WeinrothThatโs 20 times the return on a practiceโs investment to use the platform, according to eRelevance Chief Marketing Officer Adam Weinroth.
โโฆa lot of practices are not already equipped with state-of-the-art marketing. So when you have an opportunity to take on a new device that enables you to do a new procedure, if you donโt have the ability to market it very well, that takes away from some of the attractiveness and purpose of taking on that additional device,โ Mr. Weinroth says. โItโs a huge benefit to a manufacturer like BTL, where they can provide a clearer path to the device really contributing to a practiceโs revenue.โ
eRelevance offers a turnkey, cross-channel marketing solution that enables practices to run integrated promotions, not just on email but also across Facebook, Instagram, mobile apps, text, website landing pages, etc., according to Mr. Weinroth.
โTypically, for a lot of these devices, you might get a pay-off period that spans a couple of years. In our case, with BTL, weโre helping customers pay off the devices in less than six months,โ he says.
Click here to view original web page at cosmeticsurgerytimes.modernmedicine.com